10-Q: TC BioPharm Reports First Quarter 2024 Results Amidst Going Concern Uncertainty

TC BioPharm reported a net loss of $3.3 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern.

Summary

• TC BioPharm reported a net loss of $3.3 million for the three months ended March 31, 2024, compared to a net loss of $0.6 million for the same period in 2023.
• The company's research and development expenses decreased by 33% to $1.3 million, while administrative expenses decreased by 4% to $2.1 million.
• The company's cash and cash equivalents decreased to $1.0 million as of March 31, 2024, from $2.5 million at the end of 2023.
• The company has a working capital deficit of $0.6 million as of March 31, 2024.
• The company used $2.4 million in operating activities during the first quarter of 2024.
• The company is currently progressing various funding options to fill the projected working capital gap.
• Management believes that ongoing financing initiatives should provide sufficient capital to finance planned operations through 2024, but there is no certainty of success.
• The company has been focused on the development of therapeutic products based around its gamma delta T cell platform technology.
• The company has not yet generated any revenues from sales of products and expects to continue to incur significant losses in the foreseeable future.
• The company has a legal claim against it for approximately $860,000 related to a convertible loan note.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a substantial increase in net loss, a decrease in cash reserves, and a going concern warning. While there are some positive aspects, such as reduced operating expenses, the overall sentiment is negative due to the company's financial instability and dependence on future capital raises.

Positives

• Research and development expenses decreased by 33% year-over-year.
• Administrative expenses decreased by 4% year-over-year.
• The company received approximately $1.26 million from the exercise of Series D warrants.
• The company is actively pursuing various funding options to address its working capital needs.

Negatives

• The company's net loss significantly increased to $3.3 million in Q1 2024.
• The company's cash and cash equivalents decreased to $1.0 million.
• The company has a working capital deficit of $0.6 million.
• The company used $2.4 million in operating activities during the first quarter of 2024.
• The company is facing a legal claim for approximately $860,000.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's existing cash is not sufficient to fund operations for the next 12 months.
• The company's ability to continue as a going concern is in doubt.
• The company may need to raise additional capital through low-priced equity or debt financings.
• The company may need to reduce or defer spending on research and development or clinical programs.
• The company is subject to risks related to currency fluctuations, liquidity, equity price, and credit.
• The company is involved in a legal dispute regarding a convertible loan note.
• The company has not generated any revenue from product sales and is dependent on raising capital.

Future Outlook

The company expects to continue to incur significant losses in the foreseeable future and will require additional capital to fund its clinical, development, and operational requirements. Management believes that ongoing financing initiatives should provide sufficient capital to finance planned operations through 2024, and thereafter they expect to be in a position to raise significantly greater capital as the clinical program progresses.

Management Comments

• Management believes that the ongoing financing initiatives should provide sufficient capital to finance planned operations through 2024.
• Management expects to continue to raise capital routinely.
• Management believes that the company acted correctly under the terms of the convertible loan note and that no further amounts are payable to the holder.

Industry Context

The company operates in the competitive biopharmaceutical industry, focused on developing cell-based therapies. The company's focus on allogeneic gamma-delta T cell therapies and CAR-T products positions it in a growing area of immuno-oncology. The company's in-house manufacturing capabilities are a potential advantage, but the company faces significant financial challenges common to clinical-stage biotech companies.

Comparison to Industry Standards

• Many clinical-stage biotech companies experience significant losses and cash burn before achieving profitability, which is consistent with TC BioPharm's current situation.
• The company's reliance on external funding is typical for pre-revenue biotech firms, but the current going concern uncertainty is a significant concern.
• The company's focus on allogeneic cell therapies is in line with a trend in the industry towards off-the-shelf treatments, which could offer advantages over autologous therapies.
• The company's in-house manufacturing is a differentiator compared to companies that rely on contract manufacturers, potentially leading to lower costs of goods.
• The legal claim against the company is a risk that is not uncommon in the biotech industry, but the potential financial impact is a concern.

Legal Proceedings

• The company is involved in a legal dispute regarding a convertible loan note, with the claimant demanding approximately $860,000.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers and partners may be concerned about the company's ability to continue operations and deliver on its commitments.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to progress various funding options to fill the projected working capital gap.
• The company will continue to develop its gamma-delta T cell therapies and CAR-T products.
• The company will continue to defend itself against the legal claim related to the convertible loan note.

Key Dates

Keywords

TC BioPharm, Gamma-delta T cells, Immunotherapy, Clinical stage, Biopharmaceutical, AML, Going concern, Warrants, Share-based compensation, Research and development, Financial results, Operating expenses, Net loss, Capital raise